Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 2:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 185 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cellular Senescence Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

Evaluation of Geriatric Assessment and Management for Older Adults With Non-small Cell Lung Cancer Receiving Chemotherapy Radiation Therapy

NCT06139627
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8
Interventions
Best Practice, Biospecimen Collection, Communication Intervention, Comprehensive Geriatric Assessment, Electronic Health Record Review, Survey Administration
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
60 Years and older
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2031
U.S. locations
3
States / cities
Duarte, California • Rochester, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 16, 2026, 2:38 PM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Fisetin for Improving Vascular Function in Older Adults: A Phase II Clinical Trial

NCT07871162
View directory record Official record
Conditions
Aging, Endothelial Dysfunction, Cellular Senescence
Interventions
Fisetin, Placebo
Dietary Supplement · Other
Lead sponsor
University of Colorado, Boulder
Other
Eligibility
65 Years and older
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 16, 2026, 2:38 PM EDT
Completed Phase 3 Interventional

R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma

NCT00137995
View directory record Official record
Conditions
Lymphoma, Large-Cell, Diffuse
Interventions
Rituximab, Etoposide, Carboplatine, Ifosfamide + Mesna, Cisplatine, Cytosine Arabinoside, Dexamethasone, Autologous Stem Cell Transplantation, BCNU, Cytarabine, Melphalan
Drug · Procedure
Lead sponsor
Lymphoma Study Association
Other
Eligibility
18 Years to 65 Years
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 16, 2026, 2:38 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years

NCT00802464
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes zoster vaccine GSK1437173A, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
410 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
7
States / cities
Phoenix, Arizona • Pembroke Pines, Florida • Las Vegas, Nevada + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Oct 16, 2026, 2:38 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant

NCT02038153
View directory record Official record
Conditions
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission
Interventions
Laboratory Biomarker Analysis, Lenalidomide
Other · Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
60 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
The Bronx, New York • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 14, 2020 · Synced Oct 16, 2026, 2:38 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Radiosurgery for Glioblastoma Multiforme

NCT00456612
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
CyberKnife
Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
66 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 16, 2026, 2:38 PM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

Autologous Stem/Stromal Cellular Stromal Vascular Fraction (cSVF) In Frailty-Aging Processes

NCT03514537
View directory record Official record
Conditions
Frail Elderly Syndrome, Aging, Degenerative Disease
Interventions
Microcannula harvest adipose stromal tissues, Centricyte 1000, Sterile Normal Saline IV Deployment of cSVF, Liberase, Saline Solution
Procedure · Device · Drug
Lead sponsor
Healeon Medical Inc
Industry
Eligibility
40 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2028
U.S. locations
1
States / cities
Colchester, Vermont
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 16, 2026, 2:38 PM EDT
Completed Phase 2 Interventional Results available

Single Arm on the Tolerability of Weekly Nab-paclitaxel

NCT01702844
View directory record Official record
Conditions
Non Small Cell Lung Cancer (NSCLC)
Interventions
Nab-Paclitaxel
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
70 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
8
States / cities
Fayetteville, Arkansas • Chapel Hill, North Carolina • Raleigh, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 16, 2026, 2:38 PM EDT
Completed Phase 2 Interventional

Cetuximab and Vinorelbine in Elderly Subjects With Lung Cancer

NCT00165334
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Cetuximab, Vinorelbine (Navelbine)
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
70 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 22, 2009 · Synced Oct 16, 2026, 2:38 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Cellular Senescence and COVID-19 Long-Hauler Syndrome

NCT04903132
View directory record Official record
Conditions
SARS-CoV2 Infection
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 16, 2026, 2:38 PM EDT
Terminated Phase 2 Interventional

Oral Combination Chemotherapy in Treating Elderly Patients With Intermediate or High-Grade Non-Hodgkin's Lymphomas

NCT00003113
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, cyclophosphamide, etoposide, lomustine, procarbazine hydrochloride, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
60 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 17, 2011 · Synced Oct 16, 2026, 2:38 PM EDT
Recruiting Phase 3 Interventional

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

NCT04892173
View directory record Official record
Conditions
Carcinoma, Squamous Cell
Interventions
JNJ-90301900 (NBTXR3), Cetuximab, Radiation Therapy
Drug · Radiation
Lead sponsor
Johnson & Johnson Enterprise Innovation Inc.
Industry
Eligibility
60 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
26
States / cities
Birmingham, Alabama • Duarte, California • La Jolla, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 16, 2026, 2:38 PM EDT
Completed Not applicable Interventional

A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Female Subjects With Hair Loss

NCT04450602
View directory record Official record
Conditions
Androgenetic Alopecia, Androgenic Alopecia, Telogen Effluvium, Thinning Hair, Hair Loss/Baldness, Hair Thinning
Interventions
ALRV5XR, ALRV5XR Shampoo, ALRV5XR Conditioner, ALRV5XR Hair Follicle Serum (Nutriment), Placebo, Placebo Shampoo, Placebo Conditioner, Placebo Hair Follicle Serum (Nutriment)
Dietary Supplement · Other
Lead sponsor
Arbor Life Labs
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Oct 16, 2026, 2:38 PM EDT
Completed Phase 2 Interventional

Celecoxib and Docetaxel in Treating Patients With Non-Small Cell Lung Cancer

NCT00030407
View directory record Official record
Conditions
Lung Cancer
Interventions
Celecoxib, Docetaxel
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 29, 2013 · Synced Oct 16, 2026, 2:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Everycell's Effect on DNA Damage, Inflammation, and Stress

NCT02032693
View directory record Official record
Conditions
Family Member
Interventions
Everycell™, Placebo
Dietary Supplement · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 23, 2014 · Synced Oct 16, 2026, 2:38 PM EDT
Terminated Phase 2 Interventional Results available

Single Agent Versus Combination Chemotherapy to Treat High-risk Elderly With Non-small Cell Lung Cancer

NCT02590003
View directory record Official record
Conditions
Carcinoma, Non-small Cell Lung
Interventions
Carboplatin, Nab-paclitaxel
Drug
Lead sponsor
Yale University
Other
Eligibility
71 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Oct 16, 2026, 2:38 PM EDT
Not yet recruiting Phase 2 Interventional

Phase II Elderly/Frail Pts With Newly Diagnosed or Recurrent Malignant Glioma Treated With Cesium-131 GammaTile®

NCT07821112
View directory record Official record
Conditions
Glioma, Glioblastoma, GBM, Glioma, Malignant, Astrocytoma, Oligodendroglioma, Elderly Glioblastoma, Elderly GBM
Interventions
GammaTile®
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 16, 2026, 2:38 PM EDT
Recruiting No phase listed Observational

Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments

NCT06138561
View directory record Official record
Conditions
Bladder Cancer, Metastatic Bladder Cancer, Unresectable Bladder Carcinoma, Urothelial Carcinoma
Interventions
Geriatric-8 Survey, National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Bladder Symptom Index-18 (FBISI-18), Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®)
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
65 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 16, 2026, 2:38 PM EDT
Active, not recruiting Phase 1 Interventional

A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients

NCT03352765
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, bendamustine, melphalan, Autologous Stem Cell Transplantation (ASCT)
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
65 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 16, 2026, 2:38 PM EDT
Completed Phase 2 Interventional Results available

Cetuximab and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT00124618
View directory record Official record
Conditions
Lung Cancer
Interventions
cetuximab, radiation therapy
Biological · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
175
States / cities
Scottsdale, Arizona • Hollywood, Florida • Jacksonville, Florida + 107 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Oct 16, 2026, 2:38 PM EDT
Terminated Phase 2 Interventional Results available

Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients

NCT01508117
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Axitinib, Radiation Therapy
Drug · Radiation
Lead sponsor
University of Cincinnati
Other
Eligibility
70 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 19, 2017 · Synced Oct 16, 2026, 2:38 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung Cancer

NCT00351039
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Bevacizumab, Erlotinib, Pemetrexed
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
70 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 16, 2026, 2:38 PM EDT
Not yet recruiting Phase 3 Interventional

A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis

NCT06989567
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
L-citrulline, Placebo
Drug · Other
Lead sponsor
Asklepion Pharmaceuticals, LLC
Industry
Eligibility
6 Years to 21 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Coral Gables, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 16, 2026, 2:38 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)

NCT00790400
View directory record Official record
Conditions
Tuberous Sclerosis Complex (TSC), Lymphangioleiomyomatosis (LAM)
Interventions
Everolimus (RAD001), Everolimus Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
6
States / cities
Birmingham, Alabama • Phoenix, Arizona • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2017 · Synced Oct 16, 2026, 2:38 PM EDT